[1] YILDIZ B O,BOZDAG G,YAPICI Z,et al.Prevalence, phenotype and cardiometabolic risk of polycystic ovary syndrome under different diagnostic criteria[J].Hum Reprod,2012,27(10):3067-3073.
[2] MARCH W A,MOORE V M,WILLSONK J,et al.The prevalence of polycystic ovary syndrome in a community sample assessed under contrasting diagnostic criteria[J].Hum Reprod,2010,25(2):544-551.
[3] WILD R A,CARMINA E,DIAMANTI-KANDARAKIS E,et al.Assessment of cardiovascular risk and prevention of cardiovascular disease in women with the polycystic ovary syndrome:a consensus statement by the androgen excess and polycystic ovary syndrome (AE-PCOS) society[J].Clin Endocrinol Metab,2010,95(5):2038-2049.
[4] JIA H,YU L,GUO X,et al.Associations of adiponectin gene polymorphisms with polycystic ovary syndrome:a meta-analysis[J].Endocrine,2012,42(2):299-306.
[5] WITCHEL S F,RECABARREN S E,GONZALEZ F,et al.Emerging concepts about prenatal genesis,aberrant metabolism and treatment paradigms in polycystic ovary syndrome[J].Endocrine,2012,42(3):526-534.
[6] LIM S S,NORMAN R J,DAVIES M J,et al.The effect of obesity on polycystic ovary syndrome:a systematic review and meta-analysis[J].Obes Rev,2013,14(2):95-109.
[7] KANAYA N,VONDERFECHT S,CHEN S.Androgen(dihydrotestosterone)-mediated regulation of food intake and obesity in female mice[J].Steroid Biochem Mol Biol,2013,138:100-106.
[8] THEODORAKIS M J,CARLSON O,MICHOPOULOS S,et al.Human duodenal enteroendocrine cells:source of both incretin peptides,GLP-1 and GIP[J].Am J Physiol Endocrinol Metab,2006,290(3):E550-E559.
[9] TIBADUIZA E C,CHEN C,BEINBORN M.A small molecule ligand of the glucagon-like peptide 1receptor targets its amino-ter-minal hormone binding domain[J].J Biol Chem,2001,276(41):37787-37793.
[10] DEACON C F.What do we know about the secretion and degradation of incretin hormones?[J].Regul Pept,2005,128(2):117-124.
[11] MENTLEIN R Dipeptidyl-peptidase IV (CD26)-role in the inactivation of regulatory peptides[J].Regul Pept,1999,85(1):9-24.
[12] SCHIRRA J,NICOLAUS M,ROGGEL R,et al.Endogenous glucagon-like peptide 1 controls endocrine pancreatic secretion and antro-pyloro-duodenal motility in humans[J].Gut,2006,55(2):243-251.
[13] RODRIQUEZ DE FOESECA F,NAVARRO M,ALVAREZ E,et al.Peripheral versus central effects of glucagon-like peptide-1 receptor agonists on satiety and body weight loss in Zucker obese rats.[J].Metabolism,2000,49(6):709-717.
[14] LEE H,OH J Y,SUNG Y A,et al.Is insulin resistance an intrinsic defect in asian polycystic ovary syndrome?[J].Yonsei Med J,2013,54(3):609-614.
[15] 萧丽军,缪珩,吴小梅等.2型糖尿病患者胰岛素抵抗与体表测量指数的相关性分析[J].现代医学,2012,40(5):541-545.
[16] SEVER M J,KOCJAN T,PFEIFER M,et al.Short-term combined treatment with liraglutide and metformin leads to significant weight loss in obese women with polycystic ovary syndrome and previous poor response to metformin[J].Eur J Endocrinol,2014,170(3):451-459.
[17] STEPTO N K,CASSAR S,JOHAMA E,et al.Women with polycystic ovary syndrome have intrinsic insulin resistance on euglycaemic-hyperinsulaemic clamp [J].Hum Reprod,2013,28(3):777-784.
[18] SUN X,ZHENG M,SONG M,et al.Ileal interposition reduces blood glucose levels and decreases insulin resistance in a type 2 diabetes mellitus animal model by up-regulating glucagon-like peptide-1 and its receptor[J].Int J Clin Exp Pathol,2014,7(7):4136-4142.
[19] JEIPMANN A,ZAHEDI S,SIMONI M,et al.Glucagon-like peptide-1 reduces the pulsatile component of testosterone secretion in healthy males[J].Eur J Clin Invest,2005,35(9):565-572. [20 ] ELKIND-HIRSCH K,MARRIONEAUX O,BHUSHANM,et al.Comparison of single and combined treatment with exenatide and metformin on menstrual cyclicity in overweight women with polycystic ovary syndrome[J].J Clin Endocrinol Metab,2008,93(7):2670-2678.
[21] SOKOS G G,NIKOLAIDIS L A,MANKAD S,et al.Glucagonlike peptide-1 infusion improves left ventricular ejection fraction and functional status in patients with chronic heart failure[J].Card Fail,2006,12(9):694-699 .
[22] NOYAN-ASHRAF M H,MOMEN M A,BAN K,et al.GLP-1R agonist liraglutide activates cytoprotective pathways and improves outcomes after experimental myocardial infarction in mice[J].Diabetes,2009,58(4):975-983.
[23] BOSE A K,MOCANU M M,CARR R D,et al.Glucagon-like peptide 1 can directly protect the heart against ischemia/reperfusion injury[J].Diabetes,2005,54(1):146-151.
[24] WU J D,XU X H,ZHU J,et al.Effect of exenatide on inflammatory and oxidative stress markers in patients with type 2 diabetes mellitus[J].Diabetes Technol Ther,2011,13(2):143-148.
[25] HATTORI Y,JOJIMA T,TOMIZAWA A,et al.A glucagon-like peptide-1 (GLP-1) analogue,liraglutide,upregulates nitric oxide production and exerts anti-inflammatory action in endothelial cells[J].Diabetologia,2010,53(10):2256-2263.
[26] LEE Y S,PARK M S,CHOUNG J S,et al.Glucagon-like peptide-1 inhibits adipose tissue macrophage infiltration and inflammation in an obese mouse model of diabetes[J].Diabetologia,2012,55(9):2456-2468.
[27] CHAUDHURI A,GHANIM H,VORA M,et al.Exenatide exerts a potent antiinflammatory effect[J].Clin Endocrinol Metab,2012,97(1):198-207.
[28] DALMAS E,CLEMENT K,GUERRE-MILLO M.Defining macrophage phenotype and function in adipose tissue[J].Trends Immunol,2011,32(7):307-314.
[29] FUJISAKA S,USUI I,BUKHARI A,et al.Regulatory mechanisms for adipose tissue M1 and M2 macrophages in diet-induced obese mice[J].Diabetes,2009,58(11):2574-2582.
[30] HOGAN A E,TOBIN A M,AHERN T,et al.Glucagon-like peptide-1(GLP-1) and the regulation of human invariant natural killer T cells:lessons from obesity,diabetes and psoriasis[J].Diabetologia,2011,54(11):2745-2754.
[31] LYNCH L,NOWAK M,VARGHESE B,et al.Adipose tissue invariant NKT cells protect against diet-induced obesity and metabolic disorder through regulatory cytokine production[J].Immunity,2012,37(3):574-587.
[32] HOGAN A E,GAOATSWE G,LYNCH L,et al.Glucagon-like peptide 1 analogue therapy directly modulates innate immune-mediated inflammation in individuals with type 2 diabetes mellitus[J].Diabetologia,2014,57(4):781-784. |
